Tag: Alton Kremer

Eisai to Present LENVIMA® (lenvatinib) and HALAVEN® (eribulin) Data in a Variety of Advanced Cancers at ESMO 2018 Congress

  – New data on tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer to be presented in oral Proffered Paper session on Monday, Oct. 22 at 3:09 p.m. CEST   Eisai Inc. announced today the presentation of ...